Entropy Technologies’s Arcus Biosciences RCUS Stock Holding History

Entropy Technologies’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,612	Closed	-$294K	–	1173
2026 Q1	$294K	Buy	+13,612	New	+$294K	0.01%	707

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Entropy Technologies's RCUS Position: Q2 2026 in Review

Entropy Technologies sold out of Arcus Biosciences (RCUS) in Q2 2026, closing a stake of 13,612 shares — an estimated $294K sold.

Entropy Technologies first reported a position in RCUS in Q1 2026 and held it in 1 quarter. The position peaked at $294K in Q1 2026. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

Entropy Technologies reported no remaining Arcus Biosciences position as of Q2 2026 after selling out during the quarter.
Entropy Technologies sold 13,612 Arcus Biosciences shares in Q2 2026, an estimated $294K.
Entropy Technologies first reported a position in Arcus Biosciences in Q1 2026 and held it in 1 quarter.
Entropy Technologies's Arcus Biosciences position peaked at $294K in Q1 2026.
231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Entropy Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.